Mirum Pharmaceuticals, Inc. (MIRM)
98.06
+0.60
(+0.62%)
USD |
NASDAQ |
Aug 31, 16:00
98.06
0.00 (0.00%)
After-Hours: 16:34
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 6.350B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 29.03% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 9.155 |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -73.21 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 50.92% |
Profile
| Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products pipeline includes Maralixibat, Cholbam, Ctexli, Volixibat, Brelovitug, MRM-3379, and Zilurgisertib. The company was founded by Niall O'Donnel, Michael G. Grey, and Christopher Peetz in May 2018 and is headquartered in Foster City, CA. |
| URL | http://www.mirumpharma.com |
| Investor Relations URL | https://ir.mirumpharma.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Core |
| Next Earnings Release | Nov. 04, 2026 (est.) |
| Last Earnings Release | Aug. 05, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products pipeline includes Maralixibat, Cholbam, Ctexli, Volixibat, Brelovitug, MRM-3379, and Zilurgisertib. The company was founded by Niall O'Donnel, Michael G. Grey, and Christopher Peetz in May 2018 and is headquartered in Foster City, CA. |
| URL | http://www.mirumpharma.com |
| Investor Relations URL | https://ir.mirumpharma.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Core |
| Next Earnings Release | Nov. 04, 2026 (est.) |
| Last Earnings Release | Aug. 05, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |